Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

118.09 -0.13 (-0.11%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,193,443
Open 117.76
Bid (Size) 118.00 (3)
Ask (Size) 118.40 (2)
Prev. Close 118.22
Today's Range 117.14 - 118.27
52wk Range 92.94 - 148.15
Shares Outstanding N/A
Dividend Yield 1.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in... 
Via Benzinga

Performance

YTD
+15.65%
+15.65%
1 Month
-10.58%
-10.58%
3 Month
-10.23%
-10.23%
6 Month
-3.76%
-3.76%
1 Year
+20.92%
+20.92%

More News

Read More
Behind the Scenes of Novo Nordisk's Latest Options Trends
Via Benzinga
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
Via Benzinga
'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Analyst Ratings For Novo Nordisk
Via Benzinga
A Closer Look at Novo Nordisk's Options Market Dynamics
Via Benzinga
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Via The Motley Fool
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Via Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Via Benzinga
3 No-Brainer Growth Stocks to Buy in October
Via The Motley Fool
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Via MarketBeat
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
Via Benzinga
Topics Law Enforcement
Exposures Legal
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Via Benzinga
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Via Benzinga
Exposures Product Safety
2 No-Brainer Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
Via The Motley Fool
What's Going With WeightWatchers Stock On Wednesday?
Via Benzinga
Exposures Product Safety
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Via MarketBeat
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
Via The Motley Fool
Billion-Dollar News for Eli Lilly Stock Investors
Via The Motley Fool
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.